, the proposed amendments to the prohibited characteristics of major shareholders to provide greater clarity and to better reflect current risk developments. Key aspects include expanding the scope of

. DOD017/2562 May 8, 2019 Re: Management’s Discussion and Analysis (MD&A) of the Consolidated Financial Results for Quarter 1 of 2019 To: The President The Stock Exchange of Thailand DOD Biotech Public

/2561 June 19, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q1/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited

/2561 August 7, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q2/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited

of goods sold (COGS) as mentioned. Statement of Financial Position Items As at 31st Mar, 2018 As at 31st Dec, 2017 + / (-) Current Assets 2,534.8 3,118.7 (583.9) Noncurrent Assets 3,285.4 2,425.3 860.1

year which is essentially due to lower loan balances and interest rate in the current year. Income tax expenses increased by Baht 57 million as compared to the prior year and this is largely because the

situation. Net revenue of Q4/2018 is at 244.40 million baht. If comparing revenue of Q4/2018 with Q4/2017, current revenue is higher for 53.01 million baht because of consolidating revenue from subsidiary

and the price war situation. Net revenue of Q4/2018 is at 244.40 million baht. If comparing revenue of Q4/2018 with Q4/2017, current revenue is higher for 53.01 million baht because of consolidating

decrease by Baht (10.64) million Trade and other receivable decrease by Baht (13.17) million Inventories increase by Baht 4.61 million Other current assets decrease by Baht (22.69) million Investment in

debentures. Baht Million 31-Dec-18 30-Sep-19 +/(-) +/(-)% Assets Cash, Cash equivalents and current investments 138.76 120.64 (18.12) (13.06%) Trade and other accounts receivable 1,117.59 1,611.69 494.10 44.21